Sermorelin for Sleep: Off-Label Use, Evidence, Risks, and Clinical Tradeoffs
HealthRX.com
Sermorelin for sleep has no direct trial evidence
See the public record for Sermorelin
At a glance
- Approval status / No sermorelin product is FDA-approved today; Geref's approvals were withdrawn in June 2009 [4]
- Sleep evidence / Indirect only: intravenous GHRH studies, not sermorelin itself [2][3][6]
- Mechanism / GHRH analogue that prompts pituitary growth hormone release; not growth hormone [1]
- Doses studied / 30 mcg/kg subcutaneously at bedtime in children; 0.5 or 1 mg twice daily for 14 days in older men [7][8]
- Trial tolerability / 1-year pediatric trial: no adverse biochemical or hormonal changes, fasting glucose unchanged, IGF-I not excessively raised [7]
- Sport / WADA prohibits sermorelin at all times, in and out of competition [9]
- Best-supported sleep option / Cognitive behavioral therapy for insomnia is the recommended first-line treatment for chronic insomnia [10]
Is sermorelin approved for sleep, or for anything else?
Sermorelin acetate was FDA-approved as Geref under two applications: a 0.05 mg/ampule product for evaluating the pituitary's ability to secrete growth hormone, approved in December 1990, and 0.5 mg and 1 mg vials for treating idiopathic growth hormone deficiency in children with growth failure, approved in September 1997 [4]. The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, which FDA did effective June 18, 2009 [4]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [4][11].
Those approved uses were pediatric growth hormone deficiency and a diagnostic test. Geref was not approved for adults, anti-aging, weight loss or athletic performance [4], and sleep was never an approved use of any form.
With Geref gone, sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [5].
For athletes it is not merely off-label but banned. WADA's 2026 Prohibited List names sermorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times in and out of competition, and it appears again in the 2027 list that takes effect January 1, 2027 [9][12].
What do the GHRH sleep studies actually show?
Three intravenous GHRH experiments in healthy volunteers are the closest sleep findings; none tested sermorelin as a sleep treatment.
Steiger and colleagues gave 7 healthy men four 50-microgram boluses of GHRH intravenously across the night and compared the sleep EEG against placebo and somatostatin. Slow-wave sleep rose from 14.0% of the night on placebo to 20.2% on GHRH, and nocturnal cortisol was lower on GHRH (46.6 versus 61.4 ng/mL) [2].
Kerkhofs and colleagues gave a 0.3 microgram/kg intravenous bolus at three different points in the night in healthy young men. Given in early sleep, it did not change slow-wave sleep but increased REM sleep. Given during the third REM period, it markedly reduced wake and produced an almost 10-fold increase in slow-wave sleep. Given after sleep deprivation, it reduced wake time [3].
Marshall and colleagues compared 200 micrograms of GHRH given as four 50-microgram boluses with a continuous infusion and with placebo in healthy volunteers. Episodic dosing increased slow-wave sleep and REM sleep and reduced wake and stage 1 sleep versus placebo; the continuous infusion did not differ significantly from placebo [6].
All three gave intravenous GHRH to healthy volunteers with EEG recording.
What has sermorelin itself been studied for?
The main published studies of sermorelin measured growth and hormones.
In the 1-year pediatric program, 110 previously untreated prepubertal children with growth hormone deficiency received 30 micrograms/kg subcutaneously at bedtime, and 86 were evaluable. Mean height velocity rose from 4.1 cm/year at baseline to 8.0 cm/year at 6 months and 7.2 cm/year at 12 months, and 74% were good responders at 6 months [7].
In older men, 10 healthy men with a mean age of 68 received both 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily, each for 14 days, in random order, alongside 9 young men with a mean age of 26. At the high dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men. It was a short physiology study, not a trial of clinical benefit [8].
Neither study reported sleep outcomes. A 1999 review of sermorelin in children likewise describes once-daily subcutaneous dosing of 30 micrograms/kg at bedtime as effective in some prepubertal children, with height-velocity gains sustained over 12 months — growth again [1].
Why growth hormone and sleep are linked at all
In adults the most reproducible growth hormone pulse of the day arrives shortly after sleep onset, during the first stretch of slow-wave sleep. In men roughly 70% of the sleep-related growth hormone pulses coincide with slow-wave sleep, and the amount of hormone secreted during those pulses tracks the amount of slow-wave sleep at the same time [13].
Both decline with age. In a pooled study of 149 healthy men aged 16 to 83, deep slow-wave sleep fell from 18.9% of the night in early adulthood to 3.4% in midlife, and growth hormone secretion fell by 372 micrograms per decade across the same span; independently of age, the amount of growth hormone secreted was significantly associated with slow-wave sleep [14].
These are associations measured in the same nights. They do not show that raising growth hormone changes how a person sleeps, and the GHRH studies above were not designed to answer that.
What doses have been studied?
No sermorelin product is FDA-approved today, so there is no current approved dose [4]. Two regimens appear in the published work: 30 micrograms/kg subcutaneously once daily at bedtime in children with growth hormone deficiency [7], and 0.5 mg or 1 mg subcutaneously twice daily for 14 days in healthy older men [8]. The first comes from a growth study and the second from a study of hormone levels.
What the trials recorded on safety
Over one year in children, the pediatric study reported no adverse changes in general biochemical or hormonal tests, no change in fasting glucose, no excessive rise in IGF-I, and good overall tolerance [7]. In the older men, GHRH produced dose-related increases in growth hormone and IGF-I over 14 days, with the high dose bringing 24-hour growth hormone and IGF-I to levels not significantly different from young men [8].
Those windows are short — a year in children with growth hormone deficiency, 14 days in healthy older men — and they do not describe years of use in adults taking the drug for sleep.
Sleep apnea is a further complication when reading IGF-I. Among 43 men with severe obstructive sleep apnea, three months of nasal CPAP significantly raised IGF-I, total testosterone and SHBG, and the authors noted that sleep apnea may be an unrecognized confounder of the hormonal changes usually attributed to age [15].
What has stronger evidence for sleep
For chronic insomnia, the American College of Physicians recommends cognitive behavioral therapy for insomnia as the initial treatment for all adults — a strong recommendation based on moderate-quality evidence [10]. A systematic review of five randomized trials comparing CBT-I with sleep medications found low-to-moderate quality evidence that CBT-I is more effective than benzodiazepine and non-benzodiazepine drugs in the long term, while very-low-quality evidence suggested benzodiazepines were more effective in the short term [16].
The nearest thing to a growth-hormone-secretagogue sleep trial used a different molecule. A small sleep study tested MK-677, a different oral growth hormone secretagogue [17]: 8 young adults took 5 and 25 mg for 7-day periods and 6 older adults took 2 and 25 mg for 14-day periods. At the high dose, stage IV sleep rose about 50% and REM sleep by more than 20% in the young group; in the older group, treatment was associated with a nearly 50% increase in REM sleep [17]. That is a different drug, a different route and short exposure, and it does not transfer to sermorelin.
Where that leaves the tradeoff
Someone weighing sermorelin for sleep is comparing an unapproved, compounded peptide against indirect evidence from overnight intravenous GHRH studies in small groups [2][3][6]. The known tradeoffs are that FDA has not reviewed the compounded product for safety, effectiveness or quality [5] and that it is banned in sport [9]. Sleep apnea also complicates interpretation of IGF-I: levels were lower with more severe apnea in the studied men and rose after CPAP treatment in a subgroup [15].
What people on Reddit report
Short Reddit posts from people asking about sermorelin for sleep, including one whose provider declined to prescribe it, plus a reply on who it might help.
i was looking at sermorelin too cause my wife read something about it helping with sleep and recovery. my doctor in mochi also said no but i didnt push it, just dropped itRead the source discussion
Sermorelin is great if you snore or have mild sleep apnea other than that it's not going to help you.Read the source discussion
Questions worth asking
Frequently asked questions
Does sermorelin improve sleep?
Is sermorelin FDA-approved?
What dose of sermorelin was used in studies?
What side effects were recorded with sermorelin?
Can athletes use sermorelin?
What has better evidence than sermorelin for sleep?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is sermorelin peptide a steroid?
No. Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) that prompts the pituitary to release the body's own growth hormone. It is not growth hormone itself, and it is not described as a steroid.
What are the benefits of taking sermorelin peptide?
Sermorelin has not been shown to improve sleep. In a 1-year pediatric study of children with growth hormone deficiency, mean height velocity rose from 4.1 cm/year at baseline to 8.0 cm/year at 6 months and 7.2 cm/year at 12 months, and 74% were good responders at 6 months. Those are growth results, not sleep results.
References
Show all 19 referencesHide references
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(4):566-73.
- Kerkhofs M, Van Cauter E, Van Onderbergen A, Caufriez A, Thorner MO, Copinschi G. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J Physiol. 1993;264(4 Pt 1):E594-8.
- Federal Register :: Request Access.
- Official web page.
- Marshall L, Mölle M, Böschen G, Steiger A, Fehm HL, Born J. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J Clin Endocrinol Metab. 1996;81(3):1009-13.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-33.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996;128(5 Pt 2):S32-7.
- Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-8.
- Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J Clin Endocrinol Metab. 1989;68(2):352-8.
- Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13:40.
- Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86.
- Reddit participants. [deleted by user] (r/JoinMochiHealth). Accessed 2026-11-11.
- Reddit participants. sermorelin (r/BodyHackGuide). Accessed 2026-11-11.